Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.
Phase:
PHASE2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
Atrium Health Levine Cancer Institute Bristol-Myers Squibb